Search Results - "Stathopoulos, J"

Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer by Stathopoulos, G. P., Antoniou, D., Dimitroulis, J., Stathopoulos, J., Marosis, K., Michalopoulou, P.

“…Purpose Liposomal cisplatin was developed to reduce the systemic toxicity of cisplatin, particularly the nephrotoxicity, and it has been used in combination…”
Get full text

Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial by Stathopoulos, G.P., Antoniou, D., Dimitroulis, J., Michalopoulou, P., Bastas, A., Marosis, K., Stathopoulos, J., Provata, A., Yiamboudakis, P., Veldekis, D., Lolis, N., Georgatou, N., Toubis, M., Pappas, Ch, Tsoukalas, G.

“…Liposomal cisplatin is a new formulation developed to reduce the systemic toxicity of cisplatin while simultaneously improving the targeting of the drug to the…”
Get full text

Treatment of colorectal cancer with and without bevacizumab: a phase III study by Stathopoulos, G P, Batziou, C, Trafalis, D, Koutantos, J, Batzios, S, Stathopoulos, J, Legakis, J, Armakolas, A

“…The objective of this phase III trial was to compare chemotherapy combined with bevacizumab versus chemotherapy alone in the treatment of patients with…”
Get more information

Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancer by STATHOPOULOS, G. P, ARMAKOLAS, A, TRANGA, T, MARINOU, H, STATHOPOULOS, J, CHANDRINOU, H

“…Hematologic paraneoplastic alternations may not be very common, but they have been observed in a small number of patients. Granulocytosis has been described in…”
Get full text

Combination of three cytotoxic agents in small-cell lung cancer by Stathopoulos, G. P., Trafalis, D., Dimitroulis, J., Kosmas, Ch, Stathopoulos, J., Tsavdaridis, D.

“…Purpose The established treatment for small-cell lung cancer has been a cisplatin–etoposide combination, as the most effective chemotherapy regimen. Paclitaxel…”
Get full text

Two consecutive days of treatment with liposomal cisplatin in non-small cell lung cancer by STATHOPOULOS, G.P, STATHOPOULOS, J, DIMITROULIS, J

“…Liposomal cisplatin (Lipoplatin) is a new agent, a cisplatin formulation that has been investigated in a number of studies and compared with cisplatin with…”
Get full text

Liposomal Cisplatin Dose Escalation for Determining the Maximum Tolerated Dose and Dose-limiting Toxicity: A Phase I Study by STATHOPOULOS, G. P, RIGATOS, S. K, STATHOPOULOS, J

“…The aim of the present trial was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of liposomal cisplatin (lipoplatin) using…”
Get full text

Capecitabine (Xeloda) as Monotherapy in Advanced Breast and Colorectal Cancer: Effectiveness and Side-effects by STATHOPOULOS, G. P, KOUTANTOS, J, LAZAKI, H, RIGATOS, S. K, STATHOPOULOS, J, DELICONSTANTINOS, G

“…Background: Capecitabine (Xeloda) is a fluoropyrimidine which is transformed to 5-fluorouracil (5-FU) at the tumor site. The aim of the present study was to…”
Get full text

Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer by Stathopoulos, G. P., Rigatos, S. K., Dimopoulos, M. A., Giannakakis, T., Foutzilas, G., Kouroussis, C., Janninis, D., Aravantinos, G., Androulakis, N., Agelaki, S., Stathopoulos, J. G., Georgoulias, V.

“…Background: The efficacy and toxicity of gemcitabine (GEM) and irinotecan (CPT-11) is evaluated in previously untreated patients with inoperable or metastatic…”
Get full text

Epigenetic regulation on gene expression induced by physical exercise by Ntanasis-Stathopoulos, J, Tzanninis, J G, Philippou, A, Koutsilieris, M

“…It is well established that physical exercise modulates the function of many physiological systems, such as the musculoskeletal, the cardiovascular and the…”
Get full text

Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study by Stathopoulos, G P, Rigatos, S K, Fountzilas, G, Polyzos, A, Stathopoulos, J G

“…In the present study, the combination of paclitaxel and carboplatin was applied in the treatment of gastric carcinoma. This cytotoxic combination has been an…”
Get more information

Surgical Management in Lung Metastases from Colorectal Cancer by DAHABRE, J, VASILAKI, M, STATHOPOULOS, G. P, KONDAXIS, A, ILIADIS, K, PAPADOPOULOS, G, STATHOPOULOS, J, RIGATOS, S, VASILIKOS, K, KOUTANTOS, J

“…Background: Colorectal cancer is a non-aggressive slow-growing disease. Surgery is often considered for the management of metastases. Chemotherapeutical agents…”
Get full text

Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients : a phase II study by STATHOPOULOS, G. P, TSAVDARIDIS, D, MALAMOS, N. A, RIGATOS, S. K, KOSMAS, Ch, PERGANTAS, N, STATHOPOULOS, J. G, XYNOTROULAS, J

“…This is a phase II study where a novel chemotherapy combination was tested in pre-treated breast cancer patients: docetaxel and irinotecan have already been…”
Get full text

Metastatic lung disease treated with pemetrexed-docetaxel combination chemotherapy by Stathopoulos, G P, Zoublios, Ch, Stathopoulos, J

“…According to the ASCO guidelines 4 cytotoxic agents are used in colorectal cancer. Numerous agents have not been used or tested and thus their effectiveness is…”
Get more information

Maintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence by Stathopoulos, G P, Papadimitriou, Ch, Aravantinos, G, Rigatos, S K, Malamos, N, Stathopoulos, J G, Kaparelou, M, Koutantos, J, Andreadis, Ch

“…Ovarian cancer may have a high percentage of residual disease after chemotherapy. It is questionable whether second or more lines of chemotherapy are needed in…”
Get more information

Plasma VEGF levels in breast cancer patients with and without metastases by STATHOPOULOS, J, ARMAKOLAS, A, STATHOPOULOS, G.P, GOMATOS, I.P

“…Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis since it stimulates the formation of new blood vessels. Basic fibroblast growth…”
Get full text

Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer by STATHOPOULOS, G. P, MALAMOS, N. A, ARAVANTINOS, G, RIGATOS, S, CHRISTODOULOU, Ch, STATHOPOULOS, J, SKARLOS, D

“…To investigate the weekly administration of topotecan combined with paclitaxel in pretreated advanced ovarian cancer patients; our objectives were to determine…”
Get full text

Angiosarcoma of the Heart: Case Report and Review of the Literature by BATZIOS, S, MICHALOPOULOS, A, KAKLAMANIS, L, STATHOPOULOS, J, CHRISTOPOULOU, M, KOUTANTOS, J, STATHOPOULOS, G. P

“…Background: Primary angiosarcoma of the heart is an extremely rare malignant disease. Patients and Methods: A 32-year-old female with primary angiosarcoma of…”
Get full text

Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial by STATHOPOULOS, G. P, DIMITROULIS, J, ANTONIOU, D, KATIS, C, TSAVDARIDIS, D, ARMENAKI, O, MAROSIS, C, MICHALOPOULOU, P, GRIGORATOU, T, STATHOPOULOS, J

“…Our purpose was to determine the efficacy of irinotecan plus paclitaxel administered on day 1, repeated every 2 weeks, in untreated patients with advanced or…”
Get full text

OP04.05: Surgical termination of early pregnancy under interrupted ultrasound guidance by Christodoulou, C. N., Christodoulou, E. C., Stathopoulos, J. E., Tziotis, J., Kitmirides, S., Alexandrakis, G.

Get full text